B7-H4 modulator / AbbVie - LARVOL DELTA

Characterizing spatial expression patterns and prevalence of folate receptor alpha in relation to other existing and emerging ovarian cancer biomarkers (AACR 2025) - "The ovarian cancer treatment landscape has seen an emergence of biomarker-targeted therapies following accelerated approval of the folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC) mirvetuximab soravtansine-gynx (MIRV, Elahere) in November 2022 (with full US approval granted in March 2024)...HER2, Muc16, Mesothelin, TROP2, CLDN6, B7-H4, CDH6, Tissue factor and Napi2B were also evaluated by immunohistochemistry from serial sections taken from the same FFPE blocks...In addition to intensity overlap, spatial expression patterns of each biomarker relative to FRα were also evaluated to understand sequencing and combinability options. These data shed light on biomarker co-expression in ovarian cancer to best match patients to the ideal targeted therapy and to best tailor optimal combination therapies in ovarian cancer patients."

Biomarker • High Grade Serous Ovarian Cancer • Oncology • Ovarian Cancer • Solid Tumor • CDH6 • CLDN6 • FOLR1 • HER-2 • MSLN • MUC16 • SLC34A2 • VTCN1